2025-521754-41-00CompletedPhase 1
A Phase 1, Single-Center, Open-Label, Fixed-Sequence, 2-Part Study to Assess the Pharmacokinetics of IMU-838 Administered Alone and in Combination with Multiple Doses of Gemfibrozil as CYP2C8 Inhibitor, or Rifampicin as CYP2C8 Inducer, in Healthy Subjects
Source: EU CTIS (euclinicaltrials.eu) · Last updated 10 Nov 2025
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (actual)
- First submitted
- 2 Jun 2025
- Start date
- 15 Aug 2025
- Lead sponsor
- Immunic AG
- EU CT number
- 2025-521754-41-00
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 24
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Pharmaceutical Research Associates Group B.V. | Groningen | Netherlands | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.